Current treatment strategies in ANCA-positive renal vasculitis—lessons from European randomized trials

Authors: Tesa rcaron , V.; Rcaron íhová, Z.; Jan ccaron ová, E.; Ry scaron avá, R.; Merta, M.

Source: Nephrology Dialysis Transplantation, Volume 18, Supplement 1, July 2003 , pp. v2-v4(3)

Buy & download fulltext article:

Price: $42.29 plus tax (Refund Policy)

Abstract:

Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its life-threatening natural course may be modified substantially by current treatment modalities. The European Vasculitis Study Group (EUVAS) developed a subclassification of ANCA-positive vasculitides based on the disease severity at presentation, and have organized (so far) two waves of clinical trials. The first wave of randomized clinical trials had the aim of optimizing the existing therapeutic regimens; the second wave concentrated on testing some newer therapeutic approaches. Here, the design and available results of the first wave and the design of some second wave trials are reviewed briefly. The potential of the new targeted approaches (e.g. anti-tumour necrosis factor therapy) is also briefly mentioned.

Keywords: anti-neutrophil cytoplasmic antibodies; treatment; vasculitis

Document Type: Research article

DOI: http://dx.doi.org/10.1093/ndt/gfg1032

Affiliations: 1: First Medical Department, First Medical Faculty, Charles University, Prague, Czech Republic

Publication date: 2003-07-01

More about this publication?

Nephrology Dialysis Transplantation is one of the world's leading journals devoted to original clinical and laboratory research in nephrology, dialysis and transplantation. Published monthly, the journal provides an essential resource for researchers and clinicians throughout the world.